Eliaz Therapeutics
Eliaz Therapeutics: Innovating cardiovascular disease treatment via targeted therapeutic apheresis.
Founded
2015Eliaz Therapeutics: Innovating cardiovascular disease treatment via targeted therapeutic apheresis.
Eliaz Therapeutics, founded with a mission to innovate cardiovascular disease treatment, focuses on developing novel therapeutic approaches using targeted therapeutic apheresis to remove Galectin-3 from the body. Their core product, the X-GAL-3 device, aims to address cardiovascular and related diseases by reducing harmful levels of Galectin-3, a protein associated with fibrosis and inflammation. The company targets the cardiovascular disease market, with additional applications in acute kidney injury (AKI).
Notable affiliations include a collaboration with Terumo Blood Cell Technologies for the development and commercialization of their apheresis treatment. Eliaz Therapeutics has achieved significant milestones, including a $1.7 million award from the NIH for their X-GAL-3 apheresis large animal safety study. The company's innovative approach has the potential to significantly impact the treatment landscape for cardiovascular diseases and related conditions, offering new hope for patients worldwide.
Companies similar to Eliaz Therapeutics include Elastrin Therapeutics, Elgia Therapeutics, Galvanize Therapeutics and Gamma Therapeutics.
Eliaz Therapeutics was founded in 2015.
Eliaz Therapeutics' headquarters is located in Santa Rosa, CA, US.
Eliaz Therapeutics' most recent funding round was for $1.7M (USD) in June 2022.
As of Jun 23, 2022, Eliaz Therapeutics has disclosed funding of $1.7M (USD). Undisclosed round amounts are excluded.
Eliaz Therapeutics has 5 employees as of Feb 5, 2024.
Gamma Therapeutics
